Business Context and Reporting Period
Company: Vivos Therapeutics, Inc. (VVOS)
Filing Type: Form 8-K (Current Report)
Date of Report: December 20, 2022
Reporting Period Covered: This filing announces financial results for the quarters ended June 30, 2022, and September 30, 2022. The specific financial data is contained in a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the attached press release (Exhibit 99.1) but are not present in the source text provided for this summary.
Material Changes
No material changes or comparative financial data are disclosed in the text of this Form 8-K. The filing serves solely to reference the issuance of a press release regarding the Q2 and Q3 2022 results.
Guidance, Outlook, and Risks
Management Commentary: The filing notes the issuance of a press release on December 20, 2022, but does not include the text of the commentary, guidance, or outlook.
Risks and Contingencies: No specific risks or contingencies are detailed in this document. The filing includes a standard disclaimer that the information furnished (including the press release) is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except as expressly stated.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated December 20, 2022) for actual revenue, net loss, and cash position figures for the quarters ended June 30, 2022, and September 30, 2022.
- Verify the company's status as an "Emerging Growth Company" and any associated election regarding extended transition periods for accounting standards.
- Confirm the trading symbol (VVOS) and exchange (NASDAQ) for current market data.
- Check subsequent filings for the full audited or reviewed financial statements corresponding to the periods mentioned.